Given the development of complex health related technologies, the assessment of potential benefits and their related costs becomes increasingly important. It is crucial to understand the overall effects in terms of safety, clinical effectiveness, economic sustainability, ethical aspects, organisational impact, social and legal aspects to fully understand their value for patients and society overall. The assessment of the consequences related with the adoption of a new health technology should therefore include a multidimensional approach, typical of Health Technology Assessment (HTA), and the involvement of a multi-disciplinary team. For this reason, it is often not possible to perform such analysis within an organization and the support of a wide network of experts is required. The opportunity to access HTA related services is offered by EATRIS with the support of professionals with consolidated experience.
What is the aim?
To support the developers of health technologies and financing entities to highlight critical issues and benefits related with the implementation and development of the technologies, as well as gaps in the information required to conduct a complete assessment, to help them to implement new studies or to revise ongoing studies to fill those gaps.
Who is it for?
Funding organisations, research teams that deal with the development of health technologies, companies implementing health technologies solutions.
Who are the experts?
The experts vary according to the context of investigation and the domains of interest.
What does it cost?
The cost depends on the type of analysis required (early assessment, headroom type analysis, rapid HTA or full HTA) and on the number of domains investigated.
What services are provided?
Early HTA, headroom type analyses, rapid HTA and full HTA.
- Pim Munnik (Managing Director, Yumen Bionics): “As a small company focused on rare diseases, we are relying on collaborations and innovative co-funding models. The EATRIS translational assessment provided valuable insights in the health economics aspects of our prototype product. The expert insights, collected in a systematic, independent approach were a confirmation of our endeavor to address the most pressing medical need for the patients and allowed a consideration of development bottlenecks.”
What happens next?
Contact Anton Ussi with any questions and for more information through the form below.